Noroxin (norfloxacin) is a fluoroquinolone antibiotic specifically formulated to target and eliminate susceptible gram-negative and gram-positive bacteria. This second-generation quinolone demonstrates particularly potent activity against pathogens commonly responsible for complicated urinary tract infections, including Escherichia coli, Klebsiella pneumoniae, and Proteus species. Its bactericidal action occurs through inhibition of bacterial DNA gyrase and topoisomerase IV, effectively disrupting DNA replication and transcription processes. Healthcare providers frequently prescribe Noroxin for patients requiring robust antimicrobial therapy with proven efficacy against multidrug-resistant organisms.

Features

• Contains 400mg norfloxacin as the active pharmaceutical ingredient
• Available as film-coated tablets for oral administration
• Exhibits broad-spectrum activity against aerobic gram-negative bacteria
• Demonstrates reliable bioavailability with approximately 30-40% oral absorption
• Shows concentration-dependent bactericidal activity
• Maintains therapeutic concentrations in urinary tract tissues and fluids
• Manufactured under strict quality control standards meeting pharmaceutical GMP requirements
• Packaged in blister strips to ensure product stability and integrity

Benefits

• Provides rapid bactericidal action against common uropathogens within 24-48 hours of initiation
• Effectively resolves symptoms of dysuria, frequency, and urgency in complicated UTIs
• Reduces risk of infection progression to pyelonephritis or urosepsis
• Offers convenient twice-daily dosing regimen supporting treatment adherence
• Demonstrates efficacy against some β-lactamase producing strains
• Minimizes treatment duration compared to some alternative antimicrobial regimens

Common use

Noroxin is primarily indicated for the treatment of complicated urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Citrobacter freundii, Staphylococcus aureus, Staphylococcus epidermidis, and group D streptococci. The medication may also be prescribed for uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae. Off-label uses include infectious diarrhea caused by susceptible enteric pathogens and prostatitis when supported by culture and sensitivity testing. Medical practitioners should base treatment decisions on appropriate microbiological testing and local antimicrobial resistance patterns.

Dosage and direction

For complicated urinary tract infections: 400mg orally twice daily for 10-21 days, depending on infection severity and clinical response. For uncomplicated gonorrhea: single 800mg dose (two 400mg tablets). Administration should occur at least one hour before or two hours after meals to optimize absorption. Patients should maintain adequate hydration during therapy to prevent crystal formation in urine. Dosage adjustment is necessary for patients with renal impairment—for creatinine clearance ≤30 mL/min/1.73m², recommended dosage is 400mg once daily. Elderly patients may require dosage modification based on renal function assessment.

Precautions

Patients should complete the entire prescribed course even if symptoms improve to prevent development of resistance. Avoid antacids containing magnesium, aluminum, calcium, or iron supplements within 2 hours of Noroxin administration as they significantly reduce absorption. Use with caution in patients with known or suspected central nervous system disorders due to potential CNS effects including dizziness, lightheadedness, and convulsions. Tendon inflammation or rupture may occur, particularly in elderly patients and those concurrently receiving corticosteroid therapy. Photosensitivity reactions may develop; patients should avoid excessive sunlight and ultraviolet light exposure during and for several days following therapy.

Contraindications

Noroxin is contraindicated in patients with history of hypersensitivity to norfloxacin, other quinolones, or any component of the formulation. Contraindicated in patients with known prolongation of the QT interval, uncorrected hypokalemia, or those taking Class IA or III antiarrhythmic agents. Not recommended for children, adolescents under 18 years, pregnant women, or nursing mothers due to potential effects on developing cartilage. Avoid use in patients with history of tendon disorders related to quinolone administration.

Possible side effect

Common adverse reactions (≥1%) include nausea, headache, dizziness, fatigue, and abdominal discomfort. Less frequent side effects (0.1-1%) comprise photosensitivity reactions, tendon pain, sleep disturbances, and elevated liver enzymes. Rare but serious adverse events (<0.1%) include QT prolongation, torsades de pointes, peripheral neuropathy, hepatitis, pseudomembranous colitis, and severe hypersensitivity reactions including anaphylaxis. Musculoskeletal adverse events may include tendonitis, tendon rupture, arthralgia, myalgia, and gait disturbance. Psychiatric reactions such as anxiety, depression, confusion, and hallucinations have been reported.

Drug interaction

Concomitant administration with multivalent cation-containing products (antacids, sucralfate, dairy products) dramatically reduces absorption. Noroxin may increase concentrations of theophylline, caffeine, and warfarin, requiring monitoring and potential dosage adjustment. Concurrent use with nonsteroidal anti-inflammatory drugs may increase risk of CNS stimulation and seizures. Co-administration with drugs that prolong QT interval (antiarrhythmics, antipsychotics, tricyclic antidepressants, macrolides) may result in additive effects on cardiac repolarization. Probenecid may decrease renal elimination of norfloxacin, increasing systemic exposure.

Missed dose

If a dose is missed, take it as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for the missed administration. Maintain regular dosing intervals to ensure consistent antimicrobial coverage. If multiple doses are missed, contact healthcare provider for guidance on resuming therapy. Irregular dosing may contribute to subtherapeutic levels and potential development of antibiotic resistance.

Overdose

Symptoms of overdose may include nausea, vomiting, diarrhea, dizziness, headache, tremors, seizures, and mental status changes. Management should include gastric lavage or activated charcoal if ingestion occurred within two hours. Maintain adequate hydration and electrolyte balance. Hemodialysis removes approximately 10% of the administered dose and may be considered in severe cases. ECG monitoring is recommended to detect potential QT prolongation. No specific antidote exists; treatment should be symptomatic and supportive.

Storage

Store at controlled room temperature 20-25°C (68-77°F) with excursions permitted between 15-30°C (59-86°F). Protect from light and moisture. Keep container tightly closed. Do not remove tablets from blister packaging until immediately before use. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Properly discard any unused medication after completion of therapy.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Noroxin is a prescription medication that should be used only under supervision of a qualified healthcare professional. Individual response to therapy may vary based on multiple factors including pathogen susceptibility, patient comorbidities, and adherence to prescribed regimen. Healthcare providers should consult official prescribing information and current clinical guidelines before initiating therapy. Patients should report any adverse reactions to their healthcare provider promptly.

Reviews

Clinical studies demonstrate Noroxin achieves clinical cure rates of 85-92% in complicated urinary tract infections when caused by susceptible organisms. Microbiological eradication rates typically range from 82-90% at test-of-cure visit. Patients report significant improvement in UTI symptoms within 48-72 hours of initiation. Some reviews note gastrointestinal side effects as most common reason for discontinuation. Healthcare providers appreciate its reliable activity against common uropathogens and convenient dosing schedule. Continued efficacy against many multidrug-resistant strains makes it valuable in appropriate clinical scenarios despite increasing quinolone resistance in some regions.